로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CAR-T > CD19 > CD9-HA2H9

APC-Labeled Human CD19 (20-291) Protein, His TagStar Staining

  • Synonym
    CD19,B4,CVID3,MGC12802
  • Source
    APC-Labeled Human CD19 (20-291), His Tag (CD9-HA2H9) is produced via conjugation of APC to Human CD19 (20-291), His Tag with a new generation site-specific technology under Star Staining labeling platform. Human CD19 (20-291), His Tag is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
  • Molecular Characterization
    Online(Pro 20 - Lys 291) P15391-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 44.6 kDa.

  • Conjugate

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;

    2. -70°C for 3 months under sterile conditions after reconstitution.

Evaluation of CAR expression
FACS Analysis of Anti-CD19 CAR Expression
Evaluation of CAR expression

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CD19 (20-291), His Tag (Cat. No.CD9-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).

FACS Analysis of Non-specific binding to PBMCs
Evaluation of CAR expression

5e5 of PBMCs were stained with APC-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H9) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

  • Background
    B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
  • Clinical and Translational Updates

      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

코멘트 (0)


ETD of in-stock products: 4 business days

가격(KRW) : 525,000

가격(KRW) : 3,270,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:9 Details
  • Number of Drugs in Clinical Trials:181 Details
  • Latest Research Phase:Phase 3 Clinical

데이터 테이블 및 파일

DMF 신청
DMF (Drug Master File)

연락처

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

상관 제품

신제품

의문 과 코맨트

This web search service is supported by Google Inc.

totop